1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: XYL014, NCT00708812
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: simcere002, simcere0802, NCT00813332
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 2006 BAI02A02[1]-01, NCT00576914
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: XJ-EnXS0802, NCT00657423
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: ECF/endo-MGC, NCT00595972
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: Endostar B-01, XOBCR01, NCT00604435
|
|
7.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: simcere0803, NCT00813137
|
|
8.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: simcere001, simcere0801, NCT00813449
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: ENDOCX, NCT00842491
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 200902024, NCT00853684
|
|
11.
|
Phase: No phase specified Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: SIMCERE-123456, NCT00518557
|